Creon (Amylase / Lipase / Protease) - Description and Clinical Pharmacology

DESCRIPTION

CREON® 5 Capsules are orally administered and contain delayed-release MINIMI-CROSPHERES® of pancrelipase, which is of porcine pancreatic origin. Each CREON® 5 Capsule contains lipase 5,000 USP Units, protease 18,750 USP Units and amylase 16,600 USP Units.

Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose phthalate, light mineral oil and polyethylene glycol. The capsule shells contain gelatin, red iron oxide, titanium dioxide, yellow iron oxide and FD & C blue No. 2. The capsule imprinting ink contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

CLINICAL PHARMACOLOGY

The pancreatic enzymes in CREON® 5 Capsules are enteric-coated to resist gastric destruction or inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids, protein into proteoses and derived substances and starch into dextrins and short chain sugars.